Chris Kiff
About Chris Kiff
Chris Kiff is the Senior Director, WW Market Access Strategy Lead at Bristol Myers Squibb, based in Princeton, New Jersey. He has extensive experience in health economics and market access strategy, with a background in economics and health policy.
Company
Chris Kiff is currently employed at Bristol Myers Squibb, operating out of Princeton, New Jersey, United States. At Bristol Myers Squibb, he holds the position of Senior Director, WW Market Access Strategy Lead. Previously, he served as Senior Director, WW Access Strategy Genitourinary Franchise Lead, among other roles within the company.
Current Title and Responsibilities
Chris Kiff's current role at Bristol Myers Squibb is Senior Director, WW Market Access Strategy Lead. In this capacity, he is responsible for developing and implementing global market access strategies, ensuring that innovative medicines are accessible to patients across different regions.
Education and Expertise
Chris Kiff holds an MSc in Health Economics and Health Policy from the University of Birmingham, where he studied statistics, economic evaluation, modeling, health policy, and HEOR. He also has a BSc in Economics from the University of Southampton. His academic background equips him with expertise in health economics and policy, which he applies in his professional roles.
Previous Experience
Before his current role, Chris Kiff has accumulated extensive experience in the field of health economics. He worked at ICON plc as a Senior Health Economist and Health Economist in Oxford, United Kingdom. He also served as a Health Economist at the Royal College of Physicians, National Clinical Guideline Centre. Earlier in his career, he held the position of Local Marketing Representative at Cotswold Outdoor in Southampton.
Professional Skills and Contributions
Chris Kiff is recognized for his skill in obtaining endorsement from senior leaders for HTA strategies and payer value propositions. Known for managing complex situations and developing robust HTA strategies, he has also driven positive changes in the access environment via key industry forums. His motivation and expertise contribute to his role in ensuring patient access to innovative medicines.